Circulating Tumor Cells Market Predicted to Cross $11.55Bn by 2022| Key Industry Participants Fluxion Biosciences, Janssen Diagnostics

San Francisco, 10 December 2018: Global circulating tumor cells market is anticipated to reach USD 11,552.3 million by 2022, according to a new report by Grand View Research, Inc. Rising developments in the field of biomedical engineering and biomedical imaging coupled with rise in patented research initiatives by the government is expected to drive this industry through the forecast period. 

Introduction of novel technologies for enumeration of circulating tumor cells is anticipated to fuel growth in this sector through to 2022. Furthermore, increasing incidences of chronic oncology diseases that depend on the detection and analysis of CTCs, as it has enormous potential in the  real-time monitoring of cancer therapy, over the conventional methods such as imaging technologies and tumor tissue biopsy. 

Additionally, application of CTC as biomarkers for drug discovery is a promising factor for growth in the coming years. Utilization of the circulating tumor cells in development of tumor specific biomarkers in order to optimize the selection of targeted therapies and assessment of better response to the therapy is expected to support in the projected growth of CTC market in the coming years. 

Access Research Report of Circulating Tumor Cells Market @ www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market

Further key findings from the study suggest:

·       CTC enrichment accounted for the largest share of market revenue in 2014 and is expected to continue this dominance owing to high usage rates in oncology research establishments and high accuracy exhibited by this technology.

·       Microchips technology is anticipated to register substantial growth in the next seven years because of the introduction of cluster chip technology that enables capture of clusters of tumor cells for CTC quantitation.

·       Characteristic property of the cancer stem cells of self-renewal in replenishing the growing cancer is driving the attention of organizations and researchers in CTC cancer stem cell research segment thus accounting for the segment’s large share in revenue generation.

·       Application of alterations witnessed in the expression profiles of EMT-associated transcriptional regulators and their molecular targets as biomarkers in EMT study is expected to serve as an impetus for diagnosis of tumour recurrence consequently driving the segment with a double digit CAGR of over 10%.

·       North America dominated the market in 2014, with revenue estimation that accounted for over 45% of the global market. Presence of strong oncology research funding, refined healthcare infrastructure, growing incidence of cancer, favorable government initiatives with respect to R&D funding for clinical diagnostic products are factors attributive for larger revenue share.

·       Asia Pacific is anticipated to witness lucrative CAGR of over 16% as a result of infrastructure development in care centers coupled with increase in sales of CTC diagnostic tests. The need of new diagnosis methods for the growing cancer cases has gushed up research on new developments in developing economies of this region thus providing potential avenues for market growth.

·       Key participants of CTC industry include Canopus Biosciences, Clearbridge BioMedics, Fluxion Biosciences, Janssen Diagnostics, Adnagen, Advanced Cell Diagnostics, Apocell, Vitatex Inc., Miltenyi Biotech Cynvenio Biosystems, Aviva Biosciences, Biocept Inc., Biofluidica, Creatv Microtech Inc., Ikonisys Inc., Epic Biosciences, Biocep Ltd., Greiner Bio-one GmbH, Sysmex Corporation, and CellTraffix Inc.

·       These market entities are involved in collaborations with hospitals and university based research institutes in order to gain access to target population and develop novel technologies for CTC enrichment & detection.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented circulating tumor cells market on the basis of technology, application, and region: 

Global Circulating Tumor Cell Technology Outlook (Revenue, USD Million, 2012 - 2022)

·         CTC Enrichment

·         CTC Detection

·         CTC Analysis

Global Circulating Tumor Cell Application Outlook (Revenue, USD Million, 2012 - 2022)

·         Tumorigenesis research

·         EMT biomarkers development

·         Cancer stem cell research

·         Others

Circulating Tumor Cell Regional Outlook (Revenue, USD Million, 2012 - 2022)

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         MEA

Access Press Release of Circulating Tumor Cells Market@ www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Transcatheter Pulmonary Valve Market Revenue Sales to Reach $54.1 Million by 2025|Top Industry Players Direct Flow Medical

San Francisco, 10 December 2018: The global transcatheter pulmonary valve market is expected to reach a value of USD 54.1 million by 2025, according to a new report by Grand View Research, Inc. The technological advancements pertaining to heart valve technologies, and increasing number of clinical trials pipeline by various public and private players are some of the crucial factors expected to boost the market over the forecast period.

In 2015, North America held the majority of market share of nearly 80.6% in the global market. Some of the major drivers are increasing prevalence of the various cardiovascular disorders, growing geriatric population with heart valve diseases such as pulmonary stenosis, pulmonary regurgitation, and others, and rising awareness regarding the benefits of transcatheter valves over surgical procedures. The growing number of patients suffering from long-term heart disorders, rising awareness about technologically advanced heart valve, and increasing healthcare expenditures and reimbursement policies for overall transcatheter valves are some of the key contributors to the growth of the market globally.

However, Asia Pacific is expected to show a growth in this market after 2019, as there will be several product launch in this region. The Asia Pacific region is expected to grow at a lucrative growth rate owing to the growth of many developing economies like Japan and China. These developing countries show a potential of growth due to various contributors such as the increasing aging population and growing prevalence of heart diseases. Moreover, the presence of a large pool of patients, developing healthcare infrastructure & services, increasing disposable income, and rising government funding are some of the factors that are expected to drive the market during the forecast period.

Access Research Report of Transcatheter Pulmonary Valve Market @ www.grandviewresearch.com/industry-analysis/transcatheter-pulmonary-valve-market

Further key findings from the study suggest:

·       In 2015, tetralogy of Fallot (ToF) was the largest application segment, owing to the growing prevalence of ToF and the presence of huge product portfolio

·       In 2015, balloon transcatheter valve segment held majority of the revenue share and is expected to be the fastest growing market during the forecast period

·       The presence of huge patient base and growing interest among the private and public players to launch product after the completion of clinical trial in 2017 is expected to drive the Asia Pacific market

·       Some of the key players are Boston Scientific Corporation, Braile Biomédica, Direct Flow Medical, Edwards Lifesciences Corporation, JenaValve Technology, Inc., St. Jude Medical, SYMETIS, Colibri Heart Valve, LLC, VENUS MEDTECH, and XELTIS.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the transcatheter pulmonary valve market by application, technology, end-use, raw material, and region:

Transcatheter Pulmonary Valve Application Outlook (Revenue in USD Million, 2014 - 2025)

·         Cardiac Anomaly

·         Pulmonary Atresia

·         Pulmonary Stenosis

·         Pulmonary Regurgitation

·         Tetralogy of Fallot

·         Truncus Arteriosus

·         Others

Transcatheter Pulmonary Valve Technology Outlook (Revenue in USD Million, 2014 - 2025)

·         Balloon-Expanded Transcatheter Valve

·         Self-Expanded Transcatheter Valve

Transcatheter Pulmonary Valve End-Use Outlook (Revenue in USD Million, 2014 - 2025)

·         Adult

·         Pediatric

Transcatheter Pulmonary Valve Raw Material Outlook (Revenue in USD Million, 2014 - 2025)

·         Synthetic Transcatheter Valve

·         Tissue Engineered Transcatheter Valve

Transcatheter Pulmonary Valve Regional Outlook (Revenue in USD Million, 2014 - 2025)

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         MEA

Access Press Release of Transcatheter Pulmonary Valve Market@ www.grandviewresearch.com/press-release/global-transcatheter-pulmonary-valve-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

IAM Market Expected to Witness a CAGR of 12.7% through 2025| Key Industry Participants CA Technologies, NetIQ Corporation

San Francisco, 10 December 2018: The global identity and access management market size is estimated to reach USD 22.68 billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 12.7% during the forecast period. Spiraling adoption of cloud services and mobile devices and emergence of insider threats combined with strict compliance necessities are leading to increased spending on organization IT security, which is estimated to stoke the growth of the market.

Based on end use, the public sector and utilities segment accounted for the leading share in the IAM market in 2017.On the basis of deployment, cloud is anticipated to be the most promising segment during the forecast period. Cloud is changing the way a business operates. It facilitates a different level of cost-benefit, flexibility, and efficiency to carry out business functions. Moreover, it also provides organization an opportunity to transform their business models and gain a competitive edge over their competitors. Managing identities and accessing control for enterprise applications act as one of the prominent challenges faced by IT.

Extending a company’s identity services into cloud model is a notable requirement for use of on-demand computing services in long run. Various cloud delivery models such as SaaS, PaaS, and IaaS call for service providers and IT departments to extend organization’s IAM processes, practices, and procedures to cloud services that are efficient and scalable for customers and providers. Utilizing more cloud-based services puts IT security function on the forefront of a company’s planning activities, which is likely to drive the market over the forecast period.

Access Research Report of IAM Market@ www.grandviewresearch.com/industry-analysis/identity-and-access-management-iam

Further key findings from the report suggest:

·       On-premise was the most prominent deployment segment in the market in 2017. It is poised to reach USD 11.05 billion by 2025

·       The BFSI segment is projected to exhibit the highest CAGR of 14.4% during the forecast period

·       The market in Asia Pacific is estimated to experience the fastest growth in the global arena during the same period. Emerging economies such as China, India, and Japan, which are increasingly deploying IAM solutions and services to address cybersecurity concerns are playing a pivotal role in the development of the regional market

·       Key players include Oracle Corporation, IBM Corporation, CA Technologies, NetIQ Corporation, and HID Global Corporation.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/network-security-software-and-services

Grand View Research has segmented global identity and access management market on the basis deployment, end-use, and region:

Identity and Access Management Deployment Outlook (Revenue, USD Million, 2015 - 2025)

·         Cloud

·         Hybrid

·         On-Premise

Identity and Access Management End-Use Outlook (Revenue, USD Million, 2015 - 2025)

·         BFSI

·         Energy, Oil & Gas

·         Telecom & IT

·         Education

·         Healthcare

·         Public sector & utilities

·         Manufacturing

·         Others

Identity and Access Management Regional Outlook (Revenue, USD Million 2015 - 2025)

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         MEA

Access Press Release of IAM Market@ www.grandviewresearch.com/press-release/global-identity-access-management-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

Biopharmaceuticals Contract Manufacturing Market is Expected to Hit at a CAGR of 7.5% by 2025| Top Industry Players Lonza; Samsung BioLogics

San Francisco, 10 December 2018: The global biopharmaceuticals contract manufacturing market size is expected to reach USD 21.7 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 7.5% during the forecast period.

Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors driving partnerships between large molecule manufacturers and contract manufacturing organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet companies’ demand with respect to regulatory standards and new services.

Reliance of companies on CMOs for production of biologics and biosimilars is expected to rise over the forecast period as a consequence of changes adopted by CMOs. This is evident through growing investments in collaborations of companies with CMOs as well as continuous efforts taken up for broadening service portfolios.

The growth of CMOs is highly dependent on promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments in the life science sector are important opportunities that are anticipated to drive the market.

Access Research Report of Biopharmaceuticals Contract Manufacturing Market @ www.grandviewresearch.com/industry-analysis/biopharmaceuticals-contract-manufacturing-market

Further key findings from the report suggest:

·       Based on source, mammalian-based biopharmaceutical contract manufacturing captured the largest market share owing to high penetration of mammalian expression systems for biologics development

·       By service, upstream and downstream services accounted for the largest revenue share. Complexities associated with these steps pronounces demand for established contract manufacturers to ensure manufacturing processes compliant with regulatory standards

·       Biologics contract manufacturing dominated the market based on product owing to higher demand for biologics production. However, the biosimilar segment is slated to exhibit a lucrative CAGR due to cost-saving advantages associated with its development

·       Presence of effective regulatory framework for biologics development in U.S. has resulted in North America market accounting for the dominant share in 2017. However, Asia Pacific is expected to emerge as the fastest growing regional market, with developing economies expanding at a substantial pace and incorporating developments to sustain the competition

·       Several international companies are seeking outsourcing of biopharmaceutical production to Asian countries owing to continuous expansion of Asian CMOs that offer services at a reduced price, compared to service providers based in western countries

·       Some of the key service providers are Boehringer Ingelheim GmbH; Lonza; Samsung BioLogics; and FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global biopharmaceuticals contract manufacturing market on the basis of source, service, product, and region:

Biopharmaceuticals Contract Manufacturing Source Outlook (Revenue, USD Million, 2014 - 2025)

·         Mammalian

·         Non-mammalian

Biopharmaceuticals Contract Manufacturing Service Outlook (Revenue, USD Million, 2014 - 2025)

·         Process Development

·         Fill & Finish Operations

·         Analytical & QC Studies

·         Packaging

Biopharmaceuticals Contract Manufacturing Product Outlook (Revenue, USD Million, 2014 - 2025)

·         Biologics

·         Biosimilars

Biopharmaceuticals Contract Manufacturing Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East & Africa

Access Press Release of Biopharmaceuticals Contract Manufacturing Market@ www.grandviewresearch.com/press-release/global-biopharmaceuticals-contract-manufacturing-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com